Review Article

Xiao’er Xiaoji Zhike Oral Liquid Combined with Azithromycin for Mycoplasma pneumoniae Pneumonia in Children: A Systematic Review and Meta-Analysis

Table 1

Basic characteristics of included studies.

StudySize T/CSex male/femaleAgeInterventionsCourse durationOutcome measures
TCTC

Chen [11]66/6669/636.5 ± 2.46.4 ± 2.5XXZ + Azithromycin, p.o.Azithromycin, p.o.10 days①②③④⑥⑧
Gu [12]56/5684/287.1 ± 1.06.8 ± 1.1XXZ + Azithromycin, p.o.Azithromycin, p.o.1 week④⑥
Hu [13]86/8683/898.25 ± 3.718.31 ± 2.55XXZ + Azithromycin, p.o.Azithromycin, p.o.4 weeks①②③④⑦⑧
Qi [14]34/3442/264.6 ± 1.94.8 ± 2.2XXZ + Azithromycin, p.o.Azithromycin, p.o.1 week
Wang [15]32/3231/337.54 ± 2.756.32 ± 2.14XXZ + Azithromycin, p.o.Azithromycin, p.o.1 week
Xie [16]60/6061/595.19 ± 2.385.21 ± 2.46XXZ + Azithromycin, p.o.Azithromycin, p.o.1 week④⑥
Yu [17]31/3130/326.32 ± 2.126.94 ± 2.76XXZ + Azithromycin, p.o.Azithromycin, p.o.1 week
Xue [18]46/4655/375.41 ± 1.105.38 ± 1.25XXZ + Azithromycin, p.o.Azithromycin, p.o.2 weeks①②③④⑤⑥⑧
Chao [19]52/5262/425.27 ± 1.325.13 ± 1.26XXZ + Azithromycin, i.v.Azithromycin, i.v.2 weeks④⑦
Li [20]36/3539/326.6 ± 2.56.2 ± 2.1XXZ + Azithromycin, i.v.Azithromycin, i.v.2 weeks①②③④⑤
Li [21]78/7682/725.6 ± 1.35.5 ± 1.2XXZ + Azithromycin, i.v.Azithromycin, i.v.2 weeks④⑦
Li and Jin [22]63/6370/565.6 ± 1.35.5 ± 1.2XXZ + Azithromycin, i.v.Azithromycin, i.v.1 week④⑦
Zhao [23]35/3539/317.55 ± 2.067.51 ± 2.02XXZ + Azithromycin, i.v.Azithromycin, i.v.2 weeks①②③④⑤⑧
Zheng et al. [24]30/3031/298.01 ± 2.328.47 ± 2.06XXZ + Azithromycin, i.v.Azithromycin, i.v.30 days④⑥⑧
Zong [25]47/4651/423.27 ± 0.773.19 ± 0.68XXZ + Azithromycin, i.v.Azithromycin, i.v.15 days①②③④⑤

XXZ, Xiao’er Xiaoji Zhike oral liquid; T, trial group; C, control group; ①cough disappearance time, ②lung rale disappearance time, ③fever subsidence time, ④total effective rate, ⑤lung X-ray infiltrates disappearing time, ⑥immunological indexes, ⑦others, and ⑧adverse reaction.